Axonis advancing KCC2 program with $115M series A

A new $115 million series A round will give Axonis Therapeutics Inc. runway to generate data from a clinical proof-of-concept study of its lead program targeting KCC2 to treat neurological disorders. The funding was the week’s largest series A.

The biotech believes AXN-027, which potentiates activity of a potassium-chloride transporter, can be a first-in-class therapy to treat epilepsy and pain. Axonis has built its own discovery engine for KCC2 therapeutics, using internally developed assays and in vivo screening. None of the other KCC2 program in BioCentury’s BCIQ database has reached the clinic; Axonis expects to begin a first-in-human study this quarter...